Please login to the form below

Not currently logged in
Email:
Password:

GSK/SK bioscience COVID-19 vaccine to enter phase 3 trial

The study will be one of the first global phase 3 trials to compare two different COVID-19 vaccine candidates

Covid vax

South Korean company SK bioscience (SK)’s COVID-19 vaccine candidate, GBP510, will be compared directly to the AstraZeneca/Oxford University COVID-19 vaccine in a new clinical trial, GlaxoSmithKline (GSK) has announced.

Enrolling around 4,000 participants from a number of countries, the randomised, active-controlled global trial will evaluate the safety and immunogenicity of GBP510 in combination with GSK’s pandemic adjuvant.

GBP510 is a self-assembled nanoparticle vaccine candidate targeting the receptor binding domain of the SARS-CoV-2 spike protein. It is being developed by SK in collaboration with the Institute for Protein Design (IPD) at the University of Washington with support from the Bill & Melinda Gates Foundation (BMGF) and Coalition for Epidemic Preparedness Initiative (CEPI) as part of the ‘Wave 2’ vaccine investment project to develop more accessible and affordable COVID-19 vaccines.

The move to phase 3 trial follows 'promising interim data' from phase 1/2 for GBP510. In the first stage of the trial, 80 healthy adults received the adjuvanted vaccine, showing a 100% seroconversion rate, while in the second stage, no adverse events were reported by the 247 participants, which included elderly people.

The study will be one of the first global phase 3 trials to compare two different COVID-19 vaccine candidates, following French biotech Valneva’s announcement in April of phase 3 testing of its COVID-19 vaccine candidate against AstraZeneca’s Vaxzevria.

Thomas Breuer, chief global health officer, GSK said, “While many countries have made good progress with vaccination, there remains a need for accessible and affordable COVID-19 vaccines to ensure equitable access and to protect people across the world. We are pleased to contribute with GSK’s pandemic adjuvant and to be working with SK to deliver the vaccine at scale via COVAX if it is approved.”

Although GSK has been a relative latecomer in the COVID-19 vaccine race, this trial marks its second move in recent months. GSK is also supplying its adjuvant for use with a Sanofi-partnered shot, Vidprevtyn, which started a 35,000-patient phase 3 trial in May. The European Medicines Agency has already started a rolling review of the Sanofi/GSK vaccine.

Article by
Bryony Andrews

1st September 2021

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments....
Keith Berelowitz
Transforming clinical trials to accelerate drug development
...
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...